Browse the evidence

Roux-en-Y gastric bypass (RYGB) surgery is the most effective intervention for weight loss.

RYGB should be considered for patients seeking significant weight loss.

Tirzepatide increases insulin secretion, reduces glucagon release, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.

Tirzepatide can help manage blood sugar levels and weight in patients with type 2 diabetes.

Tirzepatide consistently showed reductions in HbA1c and benefits with weight loss in clinical trials.

Tirzepatide is effective for improving glycemic control and promoting weight loss in type 2 diabetes patients.

Patients with type 2 diabetes mellitus (T2DM) who followed a 3-month partial meal replacement plan achieved an average weight loss of 7.1±7.0kg at 12 months and 4.2±7.7kg at 24 months.

Implementing a partial meal replacement plan may aid in weight loss for patients with T2DM.

The proportion of participants meeting the criteria for diabetes remission increased from 8.8% at baseline to 32.4% at 24 months.

A structured dietary intervention may enhance the likelihood of diabetes remission in T2DM patients.

Bariatric interventions resulted in reductions in body mass index and hemoglobin A1c.

Bariatric surgery can lead to improvements in metabolic health markers.

The three isocaloric eating patterns, differing in carbohydrate cellularity and amount, decreased visceral fat volume significantly and to a similar clinically relevant degree.

Practitioners can consider various isocaloric diets for reducing visceral fat in obese patients.

Waist circumference was reduced to a significantly greater degree in the LCHF vs. acellular group at 6 months.

LCHF diets may be more effective for reducing waist circumference compared to acellular carbohydrate diets.

Energy intake of the slow-ER/low-ED meal was 573 kcal (50%) lower compared to the fast-ER/high-ED meal.

Practitioners should consider the impact of meal energy density and eating rate on energy intake when designing meal plans.

A slow-ER and low-ED reduced energy intake by 59% compared to the control meal.

Incorporating slower eating rates and lower energy density foods can significantly reduce caloric intake.

A fast-ER/high-ED increased energy intake by 19% compared to the control meal.

Fast eating rates and higher energy density foods can lead to increased caloric intake, which should be considered in dietary recommendations.

The ST group exhibited superior increases in leg press 1 repetition maximum (1RM) strength of -14 kg (95 % CI (-23, -5)).

Traditional strength training is more effective for increasing maximal strength compared to lighter load training.

The LLHR group showed greater strength endurance increases (65 % 1RM) of 8 repetitions (95 % CI (2, 14)).

Lighter load training can effectively improve strength endurance in middle and older adults.

Metabolic surgery results in substantial and sustained weight loss, improvements in comorbidities such as type 2 diabetes, and reduced mortality, and it is cost-effective.

Practitioners should consider metabolic surgery for patients with severe obesity and related comorbidities.

Semaglutid is approved in Germany for the treatment of obesity in adults with a BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with weight-related comorbidities.

Practitioners can consider Semaglutid as a treatment option for eligible patients with obesity.

Weight loss under Semaglutid therapy can be comparable to bariatric surgical intervention.

Semaglutid may be a viable alternative for patients who are not candidates for surgery.

Semaglutide reduces percentage body weight by a mean difference of -10.73 (95% CI -12.24 to -9.21) at medium-term follow-up.

Semaglutide can be an effective treatment option for weight loss in adults with obesity.

Semaglutide increases the proportion of people achieving 5% weight loss with a risk ratio of 2.68 (95% CI 2.30 to 3.12) at medium-term follow-up.

Semaglutide may significantly help adults with obesity achieve clinically relevant weight loss.

Tirzepatide achieved up to 20.9% weight loss over 72 weeks in non-diabetic obese individuals.

Tirzepatide can be considered an effective option for weight management in non-diabetic obese patients.

Tirzepatide significantly reduces body mass index, waist circumference, blood pressure, and atherosclerotic cardiovascular disease risk.

Tirzepatide may improve overall cardiometabolic health in non-diabetic obese patients.

GLP-1 receptor agonists are associated with greater reductions in body weight compared to lifestyle interventions and previous medications.

GLP-1 RAs may be a more effective option for weight loss compared to traditional lifestyle changes.

Discontinuation of GLP-1 receptor agonists can lead to rapid weight regain and loss of cardiometabolic benefits.

Maintaining adherence to GLP-1 RA therapy is crucial for sustained weight loss and health benefits.

Tirzepatide (TZP) reduces HbA1c levels by −2.1% compared to insulin lispro U100 added to basal insulin.

TZP may be a more effective treatment option for lowering HbA1c in patients with T2D compared to insulin lispro.

Tirzepatide induces significant weight loss: 7.5 kg (5 mg/week), 11 kg (10 mg/week), and 12 kg (15 mg/week) compared to placebo.

TZP can be considered for weight management in patients with T2D and obesity.